Answers are grounded in this paper and cite their sources.
Observational analysis reveals safety and efficacy of sublingual dexmedetomidine in agitation treatment, highlighting its potential benefits.
Sublingual dexmedetomidine under the tradename of IgalmiTM is the first and only FDA-approved sedative agent for treating agitation in schizophrenia and bipolar I or II patients. This article highlights the benefits and adverse effects associated with this novel route of administration of dexmedetomidine and its potential to emerge as a promising sedative agent.
No takes yet. Share an insight, caveat, or question.
Chittoria et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: